Market Cap 81.37M
Revenue (ttm) 154.90M
Net Income (ttm) -20.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.04%
Debt to Equity Ratio 11.85
Volume 3,045,800
Avg Vol 3,669,760
Day's Range N/A - N/A
Shares Out 189.28M
Stochastic %K 74%
Beta 1.65
Analysts Hold
Price Target $2.00

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 251 4400
Address:
25 Fenton Main Street, Suite 300, Cary, United States
Suhada_95
Suhada_95 Jul. 16 at 2:28 AM
$HRTX Hahaha, it seems a lot of people have already gotten their hands on HRTX's revenue data for the April–June period, and the funny thing is, the short sellers look terrified seeing those figures. Now, the battle between the long institutions—holding 173,282,248 shares—and the short sellers—holding 40,499,859 shares—is getting even more interesting as the Q2 report release on August 7th approaches. I’d love to see the look of fear on their faces when that Q2 report comes out, hahahahahaha.
0 · Reply
Tacto
Tacto Jul. 16 at 12:42 AM
$HRTX According to the resident FUD puppet, using one of his many accounts here, we gotta exercise "caution", so make sure that when you're loading lots and lots of HRTX, at this extraordinarily-retarded and monumentally-distorted price, you close all of your shades, turn out the lights, and be very, very quiet . . .
0 · Reply
Tacto
Tacto Jul. 16 at 12:31 AM
$HRTX Check out the CMF in the lower part of the picture below. Good stuff! . . .
0 · Reply
chance111
chance111 Jul. 15 at 10:23 PM
$HRTX One final point about the expected 40 million revenue for the second quarter. We have had other quarters like that and we are sitting at $.40. We are going to need a lot more revenue than that to move the price. 45 million would be great and maybe we will see increasing numbers each quarter. That might be difficult to achieve depending upon what happens with cinvanti
0 · Reply
chance111
chance111 Jul. 15 at 9:48 PM
$HRTX I want to apologize to @shooter40. I think. I am still not sure which quarter he was referring to when he posted about the June quarter. If he was referring to the 2nd quarter rather than the June quarter his numbers are correct compared to the 1st quarter which were lower. He referred to that quarter , I think as the March quarter. Language that is loose and not very precise, always creates miscommunication. At this point, I think he was comparing the 2nd quarter to the dismal 1st quarter. If that is what he meant, he is right. I misinterpreted what he was saying although I am not even sure about that. My only recommendation to him and actually everyone, is to try to be precise in your posts so that understand your point.
0 · Reply
chance111
chance111 Jul. 15 at 8:30 PM
$HRTX I want to caution people on here to be careful and not accept at face value the numbers that some people post on here. First there were a lot of people saying that the sales numbers for heron were so great. The numbers were ok but they have not been great. Zyn has been very disappointing. Some people are even posting false quarterly revenue numbers that are completely false. Hopefully, the false numbers were just a mistake rather than an attempt to mislead all of this. Some people might do anything to pump heron thinking it would have a positive effect on share price. We are all in this together, so I think it is despicable to mislead others on this site. I always try to be truthful and correct, but I sometimes I am wrong in my opinions. I NEVER lie about numbers and always try to post ideas for people new to heron. Just use caution when reading posts on here.
2 · Reply
Shooter40
Shooter40 Jul. 15 at 6:53 PM
$HRTX bssed in the bloomberg numbers, hrtx should exceed $14 million in zyn revenues and $4 million in Apo revenues for the june quarter total revenues should be $40 million plus
1 · Reply
Ethan11111
Ethan11111 Jul. 15 at 4:48 PM
$HRTX bloomberg terminal screenshot looks amazing. it looks way better than Q1 for sure. Over $40M revenue is mildly bullish, but the screenshot shows around $44- $45M revenue. but eventualluy we need to wait earning call for official numbers...
0 · Reply
ONLYPHARMS
ONLYPHARMS Jul. 15 at 2:18 PM
$HRTX why should collard care about retail investors they only have 10 to 15% of the total float? …… it’s not retail that he needs to make happy. We all know who it is 
1 · Reply
Braddog
Braddog Jul. 15 at 12:30 PM
$HRTX @milans100 @keypatience @chance111 @ForestFoxes @Funky1 To hear BK and Heron together scares the crap out of me and thought it deserves its own talking points I would hope that Heron will sell the company before declaring BK. Heron certainly CANNOT afford to lose one penny from Cin rev over the next 12 months. Maybe longer. Trying to be optimistic about Zyn growth rates going forward. Collard has ZERO excuses when it comes to sales growth. The partnership with CrossLink has been a big disappointment. You would think Zyn and especially APO will start to have organic growth and takeoff on their own. Start to hit critical mass! That is why the need more Zyn sales reps because Zyn needs a rep to start a surgeon the first time. That’s a lot of man hours for the reps Praying the don’t have to file a “going concern” at the next earnings What they have to say will be so important!
1 · Reply
Latest News on HRTX
Heron Therapeutics Transcript: AGM 2026

Jun 11, 2026, 9:00 AM EDT - 4 weeks ago

Heron Therapeutics Transcript: AGM 2026


Heron Therapeutics downgraded to Hold from Buy at Needham

2026-06-02T20:07:25.000Z - 6 weeks ago

Heron Therapeutics downgraded to Hold from Buy at Needham


Heron Therapeutics reports Q1 EPS (4c), consensus (2c)

2026-05-11T16:41:43.000Z - 2 months ago

Heron Therapeutics reports Q1 EPS (4c), consensus (2c)


Heron Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 8:30 AM EDT - 2 months ago

Heron Therapeutics Earnings Call Transcript: Q1 2026


Heron Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:30 AM EDT - 2 months ago

Heron Therapeutics Earnings release: Q1 2026


Heron Therapeutics Quarterly report: Q1 2026

May 11, 2026, 8:30 AM EDT - 2 months ago

Heron Therapeutics Quarterly report: Q1 2026


Heron Therapeutics Slides: Q1 2026

May 11, 2026, 8:30 AM EDT - 2 months ago

Heron Therapeutics Slides: Q1 2026


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Heron Therapeutics Earnings Call Transcript: Q4 2025


Heron Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Heron Therapeutics Annual report: Q4 2025


Heron Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Heron Therapeutics Earnings release: Q4 2025


Heron Therapeutics Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Heron Therapeutics Slides: Q4 2025


Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

2026-02-26T13:22:25.000Z - 4 months ago

Heron Therapeutics reports Q4 EPS (2c) vs 2c last year


Heron Therapeutics sees FY26 revenue $173M-$183M

2026-02-26T13:22:12.000Z - 4 months ago

Heron Therapeutics sees FY26 revenue $173M-$183M


Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

2026-01-09T14:35:13.000Z - 6 months ago

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M


Heron Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Heron Therapeutics Earnings Call Transcript: Q3 2025


Heron Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Heron Therapeutics Quarterly report: Q3 2025


Heron Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Heron Therapeutics Earnings release: Q3 2025


Heron Therapeutics Slides: Q3 2025

Nov 4, 2025, 8:30 AM EST - 9 months ago

Heron Therapeutics Slides: Q3 2025


Heron Therapeutics reports Q3 EPS (10c), consensus (1c)

2025-11-04T13:05:21.000Z - 9 months ago

Heron Therapeutics reports Q3 EPS (10c), consensus (1c)


Heron Therapeutics Proxy statement: Proxy Filing

Sep 19, 2025, 8:00 AM EDT - 10 months ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics files $125M mixed securities shelf

2025-09-09T21:15:15.000Z - 11 months ago

Heron Therapeutics files $125M mixed securities shelf


Heron Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 8:00 AM EDT - 11 months ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 8:00 AM EDT - 11 months ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Proxy statement: Proxy Filing

Sep 9, 2025, 8:00 AM EDT - 11 months ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics adopts tax benefits preservation plan

2025-08-15T11:50:16.000Z - 11 months ago

Heron Therapeutics adopts tax benefits preservation plan


Heron Therapeutics Earnings Call Transcript: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q2 2025


Heron Therapeutics Quarterly report: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q2 2025


Heron Therapeutics Earnings release: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Earnings release: Q2 2025


Heron Therapeutics Slides: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Slides: Q2 2025


Heron Therapeutics reports Q2 EPS (2c), consensus (1c)

2025-08-08T11:52:19.000Z - 1 year ago

Heron Therapeutics reports Q2 EPS (2c), consensus (1c)


Heron Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q1 2025


Heron Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings release: Q1 2025


Heron Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q1 2025


Heron Therapeutics Slides: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Slides: Q1 2025


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q4 2024


Heron Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Annual report: Q4 2024


Heron Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q4 2024


Heron Therapeutics Slides: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q4 2024


U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents


Heron Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q3 2024


Heron Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Quarterly report: Q3 2024


Heron Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q3 2024


Heron Therapeutics Slides: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q3 2024


Heron Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2024


Heron Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Quarterly report: Q2 2024


Heron Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings release: Q2 2024


Heron Therapeutics Slides: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Slides: Q2 2024


Heron Therapeutics Transcript: Investor Day 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Transcript: Investor Day 2024


Heron Therapeutics Slides: FY 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Slides: FY 2024


Heron Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q1 2024


Heron Therapeutics Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Quarterly report: Q1 2024


Heron Therapeutics Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings release: Q1 2024


Heron Therapeutics Slides: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Slides: Q1 2024


Heron Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q4 2023


Heron Therapeutics Annual report: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Annual report: Q4 2023


Heron Therapeutics Earnings release: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings release: Q4 2023


Heron Therapeutics Slides: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Slides: Q4 2023


Heron Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q3 2023


Heron Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Quarterly report: Q3 2023


Heron Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Earnings release: Q3 2023


Heron Therapeutics Slides: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Heron Therapeutics Slides: Q3 2023


Heron Therapeutics Registration statement: Registration Filing

Aug 23, 2023, 8:00 AM EDT - 3 years ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2023


Heron Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Quarterly report: Q2 2023


Heron Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings release: Q2 2023


Heron Therapeutics Slides: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Slides: Q2 2023


Suhada_95
Suhada_95 Jul. 16 at 2:28 AM
$HRTX Hahaha, it seems a lot of people have already gotten their hands on HRTX's revenue data for the April–June period, and the funny thing is, the short sellers look terrified seeing those figures. Now, the battle between the long institutions—holding 173,282,248 shares—and the short sellers—holding 40,499,859 shares—is getting even more interesting as the Q2 report release on August 7th approaches. I’d love to see the look of fear on their faces when that Q2 report comes out, hahahahahaha.
0 · Reply
Tacto
Tacto Jul. 16 at 12:42 AM
$HRTX According to the resident FUD puppet, using one of his many accounts here, we gotta exercise "caution", so make sure that when you're loading lots and lots of HRTX, at this extraordinarily-retarded and monumentally-distorted price, you close all of your shades, turn out the lights, and be very, very quiet . . .
0 · Reply
Tacto
Tacto Jul. 16 at 12:31 AM
$HRTX Check out the CMF in the lower part of the picture below. Good stuff! . . .
0 · Reply
chance111
chance111 Jul. 15 at 10:23 PM
$HRTX One final point about the expected 40 million revenue for the second quarter. We have had other quarters like that and we are sitting at $.40. We are going to need a lot more revenue than that to move the price. 45 million would be great and maybe we will see increasing numbers each quarter. That might be difficult to achieve depending upon what happens with cinvanti
0 · Reply
chance111
chance111 Jul. 15 at 9:48 PM
$HRTX I want to apologize to @shooter40. I think. I am still not sure which quarter he was referring to when he posted about the June quarter. If he was referring to the 2nd quarter rather than the June quarter his numbers are correct compared to the 1st quarter which were lower. He referred to that quarter , I think as the March quarter. Language that is loose and not very precise, always creates miscommunication. At this point, I think he was comparing the 2nd quarter to the dismal 1st quarter. If that is what he meant, he is right. I misinterpreted what he was saying although I am not even sure about that. My only recommendation to him and actually everyone, is to try to be precise in your posts so that understand your point.
0 · Reply
chance111
chance111 Jul. 15 at 8:30 PM
$HRTX I want to caution people on here to be careful and not accept at face value the numbers that some people post on here. First there were a lot of people saying that the sales numbers for heron were so great. The numbers were ok but they have not been great. Zyn has been very disappointing. Some people are even posting false quarterly revenue numbers that are completely false. Hopefully, the false numbers were just a mistake rather than an attempt to mislead all of this. Some people might do anything to pump heron thinking it would have a positive effect on share price. We are all in this together, so I think it is despicable to mislead others on this site. I always try to be truthful and correct, but I sometimes I am wrong in my opinions. I NEVER lie about numbers and always try to post ideas for people new to heron. Just use caution when reading posts on here.
2 · Reply
Shooter40
Shooter40 Jul. 15 at 6:53 PM
$HRTX bssed in the bloomberg numbers, hrtx should exceed $14 million in zyn revenues and $4 million in Apo revenues for the june quarter total revenues should be $40 million plus
1 · Reply
Ethan11111
Ethan11111 Jul. 15 at 4:48 PM
$HRTX bloomberg terminal screenshot looks amazing. it looks way better than Q1 for sure. Over $40M revenue is mildly bullish, but the screenshot shows around $44- $45M revenue. but eventualluy we need to wait earning call for official numbers...
0 · Reply
ONLYPHARMS
ONLYPHARMS Jul. 15 at 2:18 PM
$HRTX why should collard care about retail investors they only have 10 to 15% of the total float? …… it’s not retail that he needs to make happy. We all know who it is 
1 · Reply
Braddog
Braddog Jul. 15 at 12:30 PM
$HRTX @milans100 @keypatience @chance111 @ForestFoxes @Funky1 To hear BK and Heron together scares the crap out of me and thought it deserves its own talking points I would hope that Heron will sell the company before declaring BK. Heron certainly CANNOT afford to lose one penny from Cin rev over the next 12 months. Maybe longer. Trying to be optimistic about Zyn growth rates going forward. Collard has ZERO excuses when it comes to sales growth. The partnership with CrossLink has been a big disappointment. You would think Zyn and especially APO will start to have organic growth and takeoff on their own. Start to hit critical mass! That is why the need more Zyn sales reps because Zyn needs a rep to start a surgeon the first time. That’s a lot of man hours for the reps Praying the don’t have to file a “going concern” at the next earnings What they have to say will be so important!
1 · Reply
Tacto
Tacto Jul. 15 at 3:25 AM
$HRTX Holy mackerel!! "unprecedented heights" on tap... https://hymnbooks-test.bibles-direct.co.uk/content/what-investors-are-saying-heron-therapeutics-stock-is-heading-to-unprecedented-heights-1122719 . .
1 · Reply
DAP89
DAP89 Jul. 14 at 10:59 PM
$HRTX Can someone tell keypatience to unblock me ???? Not sure what I did but I must have struck a nerve somewhere.
1 · Reply
Tjshrout
Tjshrout Jul. 14 at 10:56 PM
$HRTX What was June 25? Prefer to see yoy as these months don't show me huge increases by themselves. Plus after the last qtr read vs reality not sure what can be believed anyway.
0 · Reply
bullishonHRTX
bullishonHRTX Jul. 14 at 9:41 PM
$HRTX can all of y'all loaders take a chill pill, some of us can use some fuel, so we can all get loaded together. like seriously, you guys are not trying to be the only millionaires in 2026 right?
1 · Reply
Caribbe
Caribbe Jul. 14 at 5:34 PM
$HRTX Load time I'd say
1 · Reply
keypatience
keypatience Jul. 14 at 4:30 PM
$HRTX June numbers. Smashing across the board. @Braddog @milans100
1 · Reply
Alon_R
Alon_R Jul. 14 at 3:20 PM
$HRTX ZYNRELEF's QoQ adoption (since Q1 2022) Potential pharmas considering a buyout now see the very same clear adoption in regard to ZYNRELEF, as well as the excellent growth of APONVIE. These are quality assets that will generate billions along the way, based on their methodical QoQ and YoY growth, and it is well worth it for a potential buyer to purchase the company now, before further growth of the franchises, potentially increases Heron's buyout valuation.
0 · Reply
Maissessap
Maissessap Jul. 14 at 2:09 PM
$HRTX Thanks to Azurity many here have load the boat at super cheap shareprices!, I thank them for that! Now we just need to wait for the next huge catalist: the PS.
2 · Reply
BullMaven
BullMaven Jul. 14 at 2:02 PM
$HRTX fully loaded on this and will not sell a single share. f..k shorts
0 · Reply
Braddog
Braddog Jul. 14 at 1:36 PM
$HRTX This is going no where until We get clarity on Emergency stay Azuritys launch More guidance on rev on all 3 drugs
1 · Reply
slayer2408
slayer2408 Jul. 14 at 1:31 PM
$HRTX what is a reasonable buy out price if for example this happened next month?
2 · Reply
ITrustno1
ITrustno1 Jul. 14 at 1:19 PM
$HRTX IMO 50%min to 150% SP gain within 4weeks from this SP. Time to rise …& shine
0 · Reply